Author:
Rigo Frank,Chun Seung J.,Norris Daniel A.,Hung Gene,Lee Sam,Matson John,Fey Robert A.,Gaus Hans,Hua Yimin,Grundy John S.,Krainer Adrian R.,Henry Scott P.,Bennett C. Frank
Publisher
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Subject
Pharmacology,Molecular Medicine
Reference54 articles.
1. Mouse models of SMA: tools for disease characterization and therapeutic development
2. RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
3. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?
4. Correction of disease-associated exon skipping by synthetic exon-specific activators
5. Chirboga C, Swoboda K, Darras B, Iannaccone S, Montes J, Allen H, Parad R, Johnson S, De Vivo D, Norris D et al.(2013) Results of an open-label, escalating dose study to assess the safety, tolerability, and dose range finding of a single intrathecal dose of ISIS-SMNRx in patients with spinal muscular atrophy, in 65th American Academy of Neurology Annual Meeting; 16–23 March 2013; San Diego, CA.Vol 80, ppS S36.002, American Academy of Neurology, Minneapolis, MN.
Cited by
222 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献